Literature DB >> 26358807

Proteomic and lipidomic analyses of paraoxonase defined high density lipoprotein particles: Association of paraoxonase with the anti-coagulant, protein S.

Xenia Moren1, Marie Lhomme2, Alexandre Bulla3, Jean-Charles Sanchez4, Anatol Kontush2, Richard W James1.   

Abstract

PURPOSE: Characterizing high density lipoprotein (HDL) particles and their relevance to HDL function is a major research objective. One aim is to identify functionally distinct particles. To try to limit both functional and compositional heterogeneity the present study focused on paraoxonase-1 (PON1) as a target for isolation of a minor HDL subfraction. EXPERIMENTAL
DESIGN: Immunoaffinity techniques were applied to isolate PON1-containing HDL (P-HDL) and total HDL (T-HDL), which were subsequently characterized and compared.
RESULTS: Analyses of the lipidomes showed significant differences between the fractions in the relative concentrations of individual lipid subspecies, notably reduced levels of unsaturated lysophosphatidylcholine (p < 0.05) in P-HDL (reflected in a significantly reduced total lysophosphatidylcholine polyunsaturated fatty acid content, p < 0.004). Significant differences were also observed for the proteomes. P-HDL was highly enriched in the anti-coagulant, vitamin K activated protein S (prot S) (p < 0.0001), and alpha2 macroglobulin (p < 0.01), compared to T-HDL. Conversely, procoagulant proteins kininogen 1 and histidine-rich glycoprotein were largely excluded from P-HDL. Immunoabsorption of PON1 from plasma significantly reduced prot S anti-coagulant activity. CONCLUSIONS AND CLINICAL RELEVANCE: The P-HDL lipidome and proteome showed significant differences from T-HDL. Enrichment in anti-coagulation proteins indicates complementary functionalities within P-HDL particles and underlines their anti-atherosclerotic potential.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Apolipoprotein; Atherosclerosis; Coagulation; HDL; Lipidomics

Mesh:

Substances:

Year:  2015        PMID: 26358807     DOI: 10.1002/prca.201500062

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  5 in total

Review 1.  Pharmacological Intervention to Modulate HDL: What Do We Target?

Authors:  Nicholas J Woudberg; Sarah Pedretti; Sandrine Lecour; Rainer Schulz; Nicolas Vuilleumier; Richard W James; Miguel A Frias
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

2.  Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes.

Authors:  Angelina Passaro; Giovanni Battista Vigna; Arianna Romani; Juana M Sanz; Carlotta Cavicchio; Gloria Bonaccorsi; Giuseppe Valacchi; Carlo Cervellati
Journal:  Oxid Med Cell Longev       Date:  2018-11-05       Impact factor: 6.543

3.  Endothelial Lipase Modulates Paraoxonase 1 Content and Arylesterase Activity of HDL.

Authors:  Irene Schilcher; Julia T Stadler; Margarete Lechleitner; Andelko Hrzenjak; Andrea Berghold; Gudrun Pregartner; Marie Lhomme; Michael Holzer; Melanie Korbelius; Florian Reichmann; Anna Springer; Christian Wadsack; Tobias Madl; Dagmar Kratky; Anatol Kontush; Gunther Marsche; Saša Frank
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 6.208

Review 4.  Hypertriglyceridemia and atherosclerosis.

Authors:  Jia Peng; Fei Luo; Guiyun Ruan; Ran Peng; Xiangping Li
Journal:  Lipids Health Dis       Date:  2017-12-06       Impact factor: 3.876

5.  The Association of Paraoxonase-1 Polymorphism with Carotid Artery Stenosis among Elderly Chinese Population.

Authors:  Jianyun Sun; Long Wang; Qian Yang; Taofeng Zhou; Xianhui Ding; Ke Yang; Zhiming Zhou
Journal:  Oxid Med Cell Longev       Date:  2020-02-15       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.